Skip to main content
OpenTrials
Completed

NCT Number: NCT05585931

Effect of TPN171H on Spermatogenesis

This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in healthy male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Peking University First Hospital

Beijing, Beijing Municipality, 100032, China

About this study

Safety Study in male subjects

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male aged 18~40years (included)
  • Body Mass Index of 19 to 28 kg/m2; Body weight no less than 50 kg;
  • Sperm concentration ≥15*10^6/ml, Sperm motility(a+b(%))≥32%, Semen volume ≥1.5 ml, Liquefaction time≤60 min
  • Sperm sample should be collected after a minimum of 2 days and a maximum of 7 days of sexual abstinence.
  • Take reliable contraceptive measures
  • Physical examination, vital signs examination, laboratory examination, ECG were normal or abnormal without clinical significance;
  • Be able to understand and willing to sign the Informed Consent Form;

Exclusion criteria

  • People with azoospermia, teratozoospermia, moderate-to-severe asthenozoospermia, and moderate-to-severe oligozoospermia and other abnormal semen disease
  • People with vasectomy and ligation
  • People who have a history of hypersensitivity to other PDE5 inhibitors or TPN171H;
  • There are clear diseases of the central nervous system, cardiovascular system, digestive system (including those with severe fatty liver in B-ultrasound examination), respiratory system, urinary system, blood system, metabolic disorders, etc. and require medical intervention or other unsuitable clinical trials Those with tested diseases (such as history of mental illness, etc.); those with a history of orthostatic hypotension;
  • Blurred vision or a history of the following ocular diseases: nonvascular anterior ischemic optic neuropathy (NAION), abnormal color vision, hereditary retinal degeneration (such as retinitis pigmentosa), macular degeneration;
  • A history of fainting needles or fainting blood;
  • Blood loss or blood donation of 400 mL or more within 3 months before administration;
  • Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health care products within 2 weeks before administration
  • those who have participated in other drug clinical trials and received trial drugs within 3 months before
  • Positive results of alcohol breath test, or current/previous alcoholics (drinking more than 21 standard units per week. 1 standard unit contains 14 g of alcohol, such as 360 mL of beer or 45 mL of 40% spirits or 150 mL wine);
  • Urine drug screening positive;
  • Smoking more than 10 cigarettes per day ;
  • Those who are positive for hepatitis B surface antigen (HBsAg), HCV antibody, syphilis antibody and HIV antibody;
  • he investigator believes that there are other factors that are not suitable for participating in this trial.

Treatment and study plan

TPN171H 10mg

Drug

Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.

TPN171H Placebo

Drug

Subjects were given Placebo with 240 mL warm water under fasting condition.

Primary outcomes

  1. Effect on semen function

    Time frame: 1.5 hours after taking the medicine

    The parameters of semen routine analysis were compared between TPN171H tablets and placebo.

  2. Seminal plasma exposure

    Time frame: 1.5 hours after taking the medicine

    TPN171H exposure in seminal fluid

Secondary outcomes

  1. Adverse events

    Time frame: From administration of study drug through 3 days after last administration of study drug

    adverse events (each study visit); laboratory evaluations; electrocardiogram and physical examination; vital signs will be assessed at various times during the study

Sponsors and collaborators

Lead sponsor

Vigonvita Life Sciences

Industry

Registry information

Official study title

Evaluate the Acute Effects of a Single Oral Dose of TPN171H on Semen Function in Healthy Male Subjects in China

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Oct 19, 2022
Registry last updated
Feb 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.